NORTHWEST BIOTHERAPEUTICS INC financial data

Symbol
NWBO on OTC
Location
Bethesda, MD
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 14 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 7% % -21%
Debt-to-equity -114% % -0.32%
Return On Equity 89% % -5.3%
Return On Assets -314% % -29%
Operating Margin -4363% % -39%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 1,540,682,082 shares 19%
Common Stock, Shares, Outstanding 1,518,300,000 shares 18%
Entity Public Float $510,810,000 USD -17%
Common Stock, Value, Issued $1,518,000 USD 18%
Weighted Average Number of Shares Outstanding, Basic 1,492,079 shares 19%
Weighted Average Number of Shares Outstanding, Diluted 1,492,079 shares 19%

Income Statement

Label TTM Value / Value Unit Change %
Revenues $1,336,000 USD -38%
Revenue from Contract with Customer, Excluding Assessed Tax $937,000 USD -44%
Research and Development Expense $33,754,000 USD 6.1%
General and Administrative Expense $32,092,000 USD -2.5%
Operating Income (Loss) $64,909,000 USD -2.8%
Net Income (Loss) Attributable to Parent $89,773,000 USD -29%
Earnings Per Share, Basic 0 USD/shares 38%
Earnings Per Share, Diluted 0 USD/shares 38%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value $4,560,000 USD 55%
Assets, Current $7,198,000 USD 39%
Property, Plant and Equipment, Net $16,870,000 USD -2.6%
Operating Lease, Right-of-Use Asset $4,265,000 USD -5.5%
Goodwill $626,000 USD 0%
Other Assets, Noncurrent $358,000 USD -4.3%
Assets $30,609,000 USD 4.4%
Liabilities, Current $87,905,000 USD 48%
Operating Lease, Liability, Noncurrent $4,447,000 USD -7.9%
Liabilities $125,857,000 USD 35%
Accumulated Other Comprehensive Income (Loss), Net of Tax $1,217,000 USD -4097%
Retained Earnings (Accumulated Deficit) $1,505,049,000 USD -6.3%
Stockholders' Equity Attributable to Parent $108,648,000 USD -36%
Liabilities and Equity $30,609,000 USD 4.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $9,418,000 USD 24%
Net Cash Provided by (Used in) Financing Activities $11,733,000 USD -2.9%
Net Cash Provided by (Used in) Investing Activities $93,000 USD 61%
Common Stock, Shares Authorized 1,700,000,000 shares 0%
Common Stock, Shares, Issued 1,518,300,000 shares 18%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $604,000 USD 72%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $4,560,000 USD 55%
Deferred Tax Assets, Valuation Allowance $281,221,000 USD 7.6%
Deferred Tax Assets, Gross $281,221,000 USD 7.6%
Operating Lease, Liability $4,846,000 USD -4.7%
Depreciation $400,000 USD 33%
Payments to Acquire Property, Plant, and Equipment $93,000 USD -61%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent $92,412,000 USD -24%
Lessee, Operating Lease, Liability, to be Paid $9,571,000 USD -7.3%
Operating Lease, Liability, Current $399,000 USD 56%
Lessee, Operating Lease, Liability, to be Paid, Year Two $699,000 USD -21%
Lessee, Operating Lease, Liability, to be Paid, Year One $889,000 USD -4.3%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount $4,725,000 USD -9.8%
Lessee, Operating Lease, Liability, to be Paid, Year Three $699,000 USD 0.43%
Deferred Tax Assets, Operating Loss Carryforwards $222,329,000 USD 5.1%
Preferred Stock, Shares Authorized 100,000,000 shares 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four $699,000 USD 0.43%
Operating Lease, Payments $187,000 USD -22%
Depreciation, Depletion and Amortization $400,000 USD 0%
Share-based Payment Arrangement, Expense $1,498,000 USD -67%
Interest Expense $5,732,000 USD 10%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%